Health Care & Life Sciences » Biotechnology | Otonomy Inc.

Otonomy Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
683.00
1,236.00
745
Cost of Goods Sold (COGS) incl. D&A
257.00
213.00
358.00
1,664.00
2,698.00
1,539
Gross Income
257.00
213.00
358.00
981.00
1,462.00
794
SG&A Expense
19,593.00
39,426.00
61,618.00
109,898.00
85,739.00
65,559
EBIT
19,850.00
39,639.00
61,976.00
110,879.00
87,201.00
66,353
Unusual Expense
2,833.00
3,300.00
-
602.00
4,200.00
-
Non Operating Income/Expense
14.00
101.00
111.00
1.00
-
-
Interest Expense
2,528.00
39.00
-
-
-
4
Pretax Income
19,559.00
42,877.00
61,668.00
110,583.00
90,130.00
64,668
Consolidated Net Income
19,559.00
42,877.00
61,668.00
110,583.00
90,130.00
50,368
Net Income
19,559.00
42,877.00
61,668.00
110,583.00
90,130.00
50,368
Net Income After Extraordinaries
19,559.00
42,877.00
61,668.00
110,583.00
90,130.00
50,368
Net Income Available to Common
20,098.00
42,912.00
61,668.00
110,583.00
90,130.00
50,368
EPS (Basic)
0.85
5.46
2.57
3.69
2.97
1.65
Basic Shares Outstanding
23,722.20
7,853.20
23,952.60
29,962.80
30,304.20
30,610.20
EPS (Diluted)
0.85
5.46
2.57
3.69
2.97
1.65
Diluted Shares Outstanding
23,722.20
7,853.20
23,952.60
29,962.80
30,304.20
30,610.20
EBITDA
19,593.00
39,426.00
61,618.00
110,171.00
85,912.00
65,167
Non-Operating Interest Income
-
-
419.00
899.00
1,271.00
1,689
Preferred Dividends
539.00
35.00
-
-
-
-

About Otonomy

View Profile
Address
4796 Executive Drive
San Diego California 92121
United States
Employees -
Website http://www.otonomy.com
Updated 07/08/2019
Otonomy, Inc. is a biopharmaceutical company, which engages in the research, development, and manufacture of therapeutics for otology. The firm's portfolio includes therapeutics for diseases and disorders of the ear such as Ménière's disease, tinnitus, synaptopathy hearing loss, cisplatin-induced loss, severe hearing loss, TTP surgery, and acute otitis externa. It operates under the Otiprio brand.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.